TCAF2 (TRPM8 channel-associated factor 2) is a membrane-associated protein that functions as a negative regulator of the TRPM8 cold-sensor cation channel while promoting its trafficking to the plasma membrane 1. TCAF2 exhibits opposing regulatory effects compared to its paralog TCAF1, antagonistically modulating TRPM8 activity across multiple tissues 2. Mechanistically, TCAF2 inhibits TRPM8 expression and activity, leading to downstream effects including Wnt5a secretion and JAK2/STAT3 pathway activation 34. Clinically, TCAF2 functions as an oncogene across multiple cancer types. In colorectal cancer, TCAF2 overexpression in pericytes promotes liver metastasis and correlates with poor prognosis 3. In glioma, elevated TCAF2 correlates with tumor grade and independently predicts poor prognosis, driving cell migration and invasion through EMT-like processes via STAT3 signaling 56. Similarly, in gastric cancer, TCAF2 mediates PDE12-driven proliferation, migration, and EMT through JAK2/STAT3 activation 4. Additionally, TCAF2 serves as a component of hypoxic gene expression signatures, being upregulated in hypoxic tumor microenvironments and downregulated by hyperbaric oxygen therapy in glioblastoma 78. These findings position TCAF2 as both a diagnostic biomarker and potential therapeutic target in cancer progression.